Alimera Sciences Statistics
Share Statistics
Alimera Sciences has 54.38M
shares outstanding. The number of shares has increased by 3.81%
in one year.
| Shares Outstanding | 54.38M |
| Shares Change (YoY) | 3.81% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 85.26% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,404,657 |
| FTD / Avg. Volume | 392.77% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -5.49 and the forward
PE ratio is null.
Alimera Sciences's PEG ratio is
0.08.
| PE Ratio | -5.49 |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| Forward PS | n/a |
| PB Ratio | 2.39 |
| P/FCF Ratio | -1.23 |
| PEG Ratio | 0.08 |
Financial Ratio HistoryEnterprise Valuation
Alimera Sciences has an Enterprise Value (EV) of 165.74M.
| EV / Sales | 2.05 |
| EV / EBITDA | 22.78 |
| EV / EBIT | -11.62 |
| EV / FCF | -1.85 |
Financial Position
The company has a current ratio of 2.39,
with a Debt / Equity ratio of 1.4.
| Current Ratio | 2.39 |
| Quick Ratio | 2.31 |
| Debt / Equity | 1.4 |
| Debt / EBITDA | 9.26 |
| Debt / FCF | -0.75 |
| Interest Coverage | -0.14 |
Financial Efficiency
Return on Equity is -43.6% and Return on Invested Capital is -1.33%.
| Return on Equity | -43.6% |
| Return on Assets | -13.11% |
| Return on Invested Capital | -1.33% |
| Revenue Per Employee | $524,376.62 |
| Profits Per Employee | $-130,727.27 |
| Employee Count | 154 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 10.42 |
Taxes
| Income Tax | 85K |
| Effective Tax Rate | -0.42% |
Stock Price Statistics
The stock price has increased by 52.62% in the
last 52 weeks. The beta is 1.25, so Alimera Sciences's
price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | 52.62% |
| 50-Day Moving Average | 5.56 |
| 200-Day Moving Average | 4.21 |
| Relative Strength Index (RSI) | 52.49 |
| Average Volume (20 Days) | 866,825 |
Income Statement
In the last 12 months, Alimera Sciences had revenue of 80.75M
and earned -20.13M
in profits. Earnings per share was -0.79.
| Revenue | 80.75M |
| Gross Profit | 61.17M |
| Operating Income | -1.47M |
| Net Income | -20.13M |
| EBITDA | 7.28M |
| EBIT | -9.86M |
| Earnings Per Share (EPS) | -0.79 |
Full Income StatementBalance Sheet
The company has 12.09M in cash and 67.4M in
debt, giving a net cash position of -55.31M.
| Cash & Cash Equivalents | 12.09M |
| Total Debt | 67.4M |
| Net Cash | -55.31M |
| Retained Earnings | -418.49M |
| Total Assets | 150.38M |
| Working Capital | 35.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -14.26M
and capital expenditures -75.53M, giving a free cash flow of -89.79M.
| Operating Cash Flow | -14.26M |
| Capital Expenditures | -75.53M |
| Free Cash Flow | -89.79M |
| FCF Per Share | -3.51 |
Full Cash Flow StatementMargins
Gross margin is 75.75%, with operating and profit margins of -1.82% and -24.93%.
| Gross Margin | 75.75% |
| Operating Margin | -1.82% |
| Pretax Margin | -24.82% |
| Profit Margin | -24.93% |
| EBITDA Margin | 9.01% |
| EBIT Margin | -1.82% |
| FCF Margin | -111.19% |
